Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma

Investor logo

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

MUTHU RAJA Karthick Raja KOVÁŘOVÁ Lucie HÁJEK Roman

Year of publication 2012
Type Article in Periodical
Magazine / Source Leukemia & Lymphoma
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.3109/10428194.2011.652106
Field Oncology and hematology
Keywords lenalidomide; dexamethasone; multiple myeloma
Attached files
Description The introduction of novel drugs (thalidomide, lenalidomide [immunomodulatory drugs; IMiDs] and bortezomib) optimistically changed the outcome of patients with multiple myeloma (MM) in terms of progressionfree and overall survival when compared to conventional chemotherapies.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.